For decades, aspirin has worn the crown as the go-to pill for keeping heart disease at bay. A tiny tablet, a household name, and hailed as a lifesaver. But a new study says another drug called clopidogrel might be ready to snatch the spotlight. The study, published in The Lancet and showcased at the European Society of Cardiology (ESC) Congress in Madrid, analysed seven clinical trials. That is nearly 29,000 patients with coronary artery disease (CAD) under the microscope.

CAD is what happens when fatty gunk (plaque) clogs up your coronary arteries, putting you on the fast track to heart attacks and strokes.

Half the patients were put on aspirin, the age-old defender of arteries. The other half were handed clopidogrel, a lesser-known antiplatelet drug that prevents blood cells from clumping together into dangerous clots. And the clopidogrel group had a 14 per cent lower risk of scary outcomes like strokes, heart attacks, or even death.

And rates of major bleeding — one of the biggest worries with blood thinners — were no worse than with aspirin.

What Did the Experts Say?

Researchers did not mince their words. They concluded that clopidogrel “offers superior protection against major cardiovascular and cerebrovascular events compared with aspirin, without an excess risk of bleeding.”

Even stronger, they said: “These results support a preference for clopidogrel over aspirin for chronic antiplatelet monotherapy for patients with stable CAD.”

And for those worried about costs, availability, or whether clopidogrel will mean taking out a small loan at the pharmacy, researchers reassured: “The widespread availability, generic formulation, and affordability of clopidogrel further supports its potential for extensive adoption in clinical practice.”

Why Does This Matter?

Aspirin is practically medical royalty. For years, patients with CAD were told to take it indefinitely, usually in low doses. The logic was simple: aspirin makes blood less sticky, so the chances of clots clogging up those already narrowed arteries drop.

But aspirin is not without its flaws. Long-term use can irritate the stomach and, more worryingly, increase the risk of major bleeding. Doctors have tolerated this risk because the heart benefits outweighed the downsides. Until now, perhaps.

If clopidogrel can give patients better protection without adding extra bleeding danger, it could flip decades of medical wisdom on its head.

The British Heart Foundation Weighs In

Reacting to the findings, Professor Bryan Williams, chief scientific and medical officer at the British Heart Foundation, acknowledged the potential shake-up.

“Aspirin is a commonly prescribed drug to help prevent repeat heart attacks and strokes,” he said. “This research suggests that clopidogrel, an alternative to aspirin, might be more effective at preventing recurrent heart attacks or strokes. Importantly, these benefits come without a greater risk of major bleeding.

“These findings are likely to impact the medications doctors prescribe to their patients to reduce their risk of future heart problems.”

What Patients Should Know

If you are one of the millions of people popping an aspirin a day, do not chuck your tablets in the bin just yet. Experts are not advising patients to swap medications on their own. But the findings will almost certainly fuel conversations between cardiologists and their patients.

Doctors may start leaning more towards clopidogrel, particularly for people with stable CAD who are expected to stay on antiplatelet therapy for the long haul. With its generic version already widely available, the shift could be smoother and faster than most medical revolutions.

Aspirin is cheap, it is trusted, and it has saved countless lives. But medicine does not stand still. Clopidogrel might just be the upgrade the cardiology world did not know it needed. The real test will be whether global health guidelines change in the wake of this research.

Individuals using one of the UK’s most frequently prescribed painkillers should know about a rare side effect that can cause a severe burning sensation in the stomach. While this medication is widely used and taken regularly by many, health experts have now issued a warning regarding this potential reaction.

‘Burning Stomach’ Warning Over This Common Painkiller

Naproxen is a non-steroidal anti-inflammatory drug (NSAID), part of the same group as ibuprofen and aspirin. It helps reduce pain, inflammation, and swelling in muscles and joints. Doctors may prescribe it in tablet or liquid form for conditions like rheumatoid arthritis, osteoarthritis, gout, and menstrual cramps.

It’s also used to treat certain muscle or bone problems, including back pain, sprains, and strains. The duration of treatment can vary, some people only need a few days, while others may require longer-term prescriptions. If you take naproxen for an extended period, your doctor may also prescribe medication to reduce the risk of side effects.

According to the NHS, your naproxen dose depends on why you are taking it, your age, liver and kidney function, and how well it relieves your symptoms. Older adults and people with heart, liver, or kidney issues usually receive lower doses. For children, the dose is calculated based on weight.

Naproxen Side Effects

Like all medications, naproxen can cause side effects, though not everyone experiences them. Common issues, affecting about 1 in 100 people, include:

• Confusion
• Headache
• Ringing in the ears
• Vision changes
• Drowsiness or fatigue
• Dizziness
• Skin rashes

If any side effect persists or causes discomfort, speak with a doctor or pharmacist. In rare cases, naproxen can lead to severe stomach problems, such as intense indigestion, heartburn, or abdominal pain, which may indicate an ulcer or inflammation, according to the NHS.

Naproxen: NHS Issues Warning Over Naproxen

The NHS website claims: "Your doctor may tell you not to take naproxen if you have a stomach ulcer or you have had one in the past. If you need to take naproxen but are at risk of getting a stomach ulcer, your doctor may prescribe another medicine for you to take alongside naproxen to protect your stomach.”

The most common symptom of a stomach ulcer is a burning or gnawing pain in the centre of the stomach. But stomach ulcers are not always painful and some people may have other symptoms, such as indigestion, heartburn and feeling sick.

If you think you may have symptoms of a stomach ulcer, stop taking naproxen and contact your doctor. You can report any suspected side effect using the Yellow Card safety scheme.

The US Food and Drug Administration has given the green light to a new once-daily pill that works without hormones to ease moderate to severe hot flashes in menopausal women, Bayer announced Friday. The drug, called elinzanetant, will be available in the US starting in November under the brand name Lynkuet, according to Bayer.

It works by targeting brain chemicals responsible for hot flashes and night sweats, medically referred to as vasomotor symptoms. Experts estimate that over 80% of women experience hot flashes during menopause.

“This FDA approval marks a bold leap forward, our first non-hormonal treatment for vasomotor symptoms of menopause,” said Christine Roth, Bayer’s executive vice president of global product strategy and commercialization, in a news release Friday. “There’s a growing need for personalized approaches to menopause care, and Lynkuet fills a crucial gap in treatment options.”

For many women, hormone therapy can be a safe and effective way to manage symptoms like hot flashes. However, some women with certain health conditions or a history of diseases, including specific cancers, are sometimes advised against hormone replacement therapy. In such cases, alternative options like Lynkuet may be particularly valuable.

Clinical Trial Shows Promising Results

A Phase 3 clinical trial involving 628 postmenopausal women found that those taking elinzanetant for 12 weeks saw more than a 73% reduction in the frequency of their vasomotor symptoms, compared with a 47% reduction in those who received a placebo. The most commonly reported side effects were drowsiness, fatigue, and headaches.

“This year-long study not only confirmed rapid and substantial relief from the frequency and severity of hot flashes and night sweats but also showed that these benefits lasted for a full year, offering hope for long-term symptom control,” said Dr. JoAnn Pinkerton, director of midlife health at UVA Health and emeritus executive director of the North American Menopause Society, when the trial results were published.

“For women facing moderate to severe vasomotor symptoms during menopause, treatment options have been limited, especially for those who cannot or prefer not to use hormone therapy,” Pinkerton added. “Severe hot flashes can disrupt daily life, work, and home routines, highlighting the need for effective non-hormonal treatments.”

Hot Flashes and Night Sweats

Hot flashes are sudden, intense feelings of heat that usually affect the face, chest, and head. They can bring on heavy sweating and flushing for several minutes. Nighttime episodes are called night sweats. Women can experience hot flashes sporadically or multiple times a day, making them highly disruptive.

“It’s important that women know there are choices to treat moderate to severe hot flashes, and this approval gives healthcare providers another option,” said Claire Gill, president and founder of the National Menopause Foundation, in Bayer’s announcement.

A New Era of Menopause Treatment

In 2023, the FDA approved another non-hormonal menopause drug, fezolinetant, which also provides an alternative to traditional hormone therapies for hot flashes. Fezolinetant and elinzanetant are among the first drugs to target a recently discovered brain pathway involved in regulating hot flashes.

During menopause, declining estrogen levels trigger overactive nerves in the hypothalamus, a small region deep in the brain that helps control the body’s thermostat. These nerves release too many chemical signals called neurokinins. Both drugs block neurokinin receptors on brain cells, reducing the signals that trigger hot flashes.

“Severe hot flashes can significantly affect daily life,” Pinkerton said. “This approval gives healthcare providers a new, first-line option to help women with moderate to severe menopause-related hot flashes.”

Health officials in the UK have issued a 48-hour warning after a rise in cases of an “unpleasant” winter bug. The UK Health Security Agency (UKHSA) has urged people to stay home for two days after symptoms subside to help stop the spread of norovirus, commonly known as the “winter vomiting bug.” The virus, which causes vomiting and diarrhoea, spreads easily, particularly in colder months.

Recent data shows that cases have started to climb across England in recent weeks. The NHS has supported the UKHSA’s advice, reminding people to remain at home for at least 48 hours after symptoms clear to avoid infecting others.

What Is The Winter Bug Spreading In UK?

Norovirus is a highly contagious group of viruses that cause sudden vomiting and diarrhea. It spreads easily through contaminated food, water, and surfaces, and is known to peak during the colder months. In fact, it’s the leading cause of foodborne illness in the United States.

The virus was first identified in 1968 after an outbreak in an elementary school in Norwalk, Ohio, which gave it its original name, the Norwalk virus.

Norovirus vs. the Stomach Flu

Although often called the “stomach flu,” norovirus is not related to influenza. The flu virus affects the respiratory system, while norovirus targets the digestive tract, causing gastroenteritis.

Types of Norovirus

Norovirus belongs to the Caliciviridae family and includes 10 groups with around 48 known types. Among these, the GII.4 strain is the one most often linked to widespread outbreaks.

Unique Symptoms of Norovirus

Here are some less-covered but important unique symptoms of Norovirus infection to watch for:

• A sudden, intense onset of vomiting and watery diarrhoea, often without warning.
• Rapid loss of appetite and stomach cramps that may begin only 12 to 48 hours after exposure.
• Feeling unwell with low-grade fever, head or body aches, chills or muscle pain that accompany the GI symptoms.
• Signs of dehydration early on, such as dark urine, dry mouth, faintness on standing, or crying with few or no tears especially in children, older adults or immune-weakened people.

Unusual how quickly it hits and how short-lived it often is: many people recover in 1-3 days, yet they can still spread the virus for days after symptoms stop

To help stop the virus from spreading, the NHS has urged people with symptoms to take extra care, as per NHS. Those affected should:

• Avoid going to work, school, or nursery until at least 48 hours after their last episode of vomiting or diarrhoea.
• Refrain from visiting hospitals, care homes, or other vulnerable settings during the same period.
• These precautions are crucial because norovirus remains highly contagious even after symptoms appear to have cleared.

How to Stop Norovirus from Spreading

Contaminated food and water can also transmit the virus. Along with staying home while you’re unwell, the NHS recommends taking the following precautions to reduce the risk of passing it on:

Wash your hands thoroughly with soap and warm water after using the toilet or changing nappies, alcohol-based hand gels do not kill norovirus.

• Clean your hands before handling food, whether you’re cooking, serving, or eating.
• Launder soiled clothes and bedding separately at 60°C if they’ve come into contact with vomit or stool.
• Disinfect frequently touched surfaces, including toilet seats, taps, flush handles, and door handles.
• Limit physical contact with others until you’ve been symptom-free for at least two days.